These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 23689820

  • 21. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA, Schumock GT, Bartle B, Pickard AS.
    Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
    [Abstract] [Full Text] [Related]

  • 22. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM, Beier J.
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [Abstract] [Full Text] [Related]

  • 23. Inhaled Long-acting Anticholinergics and Urinary Tract Infection in Individuals with COPD.
    Gershon AS, Newman AM, Fischer HD, Austin PC, Daneman N, Bell CM, Stephenson AL, Gill SS, Vozoris NT, Rochon PA.
    COPD; 2017 Feb; 14(1):105-112. PubMed ID: 27732117
    [Abstract] [Full Text] [Related]

  • 24. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY study investigators.
    Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587
    [Abstract] [Full Text] [Related]

  • 25. Long-acting inhaled bronchodilators for COPD--lack of logic continues.
    Jones D.
    N Z Med J; 2005 Sep 16; 118(1222):U1669. PubMed ID: 16222360
    [Abstract] [Full Text] [Related]

  • 26. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC, Lau H, La HO, Choi IS, Geba GP.
    Curr Med Res Opin; 2010 Feb 16; 26(2):297-306. PubMed ID: 19961283
    [Abstract] [Full Text] [Related]

  • 27. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 16; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 28. Inhaled drugs as risk factors for community-acquired pneumonia.
    Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A, Community-Acquired Pneumonia in Catalan Countries.
    Eur Respir J; 2010 Nov 16; 36(5):1080-7. PubMed ID: 20525710
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Pneumology. Should we fear inhaled anticholinergic bronchodilators?].
    Rochat T, Janssens JP.
    Rev Med Suisse; 2009 Jan 14; 5(186):135-7. PubMed ID: 19238933
    [Abstract] [Full Text] [Related]

  • 32. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety.
    Tashkin DP.
    Curr Opin Pulm Med; 2010 Mar 14; 16(2):97-105. PubMed ID: 20019615
    [Abstract] [Full Text] [Related]

  • 33. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
    Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P, American College of Physicians, American College of Chest Physicians, American Thoracic Society, European Respiratory Society.
    Ann Intern Med; 2011 Aug 02; 155(3):179-91. PubMed ID: 21810710
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents.
    Alzayer R, Hughes J, Parsons R, Lee YP.
    Qual Prim Care; 2010 Aug 02; 18(3):189-99. PubMed ID: 20659403
    [Abstract] [Full Text] [Related]

  • 36. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
    Singh S, Loke YK, Enright P, Furberg CD.
    Thorax; 2013 Jan 02; 68(1):114-6. PubMed ID: 22764216
    [Abstract] [Full Text] [Related]

  • 37. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM.
    Respir Med; 2007 Jul 02; 101(7):1398-405. PubMed ID: 17368011
    [Abstract] [Full Text] [Related]

  • 38. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Singh S, Loke YK, Furberg CD.
    JAMA; 2008 Sep 24; 300(12):1439-50. PubMed ID: 18812535
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern of cardiovascular safety?
    McIvor RA.
    Pol Arch Med Wewn; 2009 Nov 24; 119(11):697-8. PubMed ID: 19920792
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.